Physician profile
David Sikes
NPI 1710098215
$17,508.01
in general payments reported to CMS, 2019-2025
45 companies · $825 in 2025
The $825 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,217 · 2020: $2,114 · 2021: $2,710 · 2022: $3,018 · 2023: $3,455 · 2024: $2,168 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,348 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,348.37 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,054.19 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $2,380.53 | 2019-2025 | |
| Amgen INC. | $1,863.90 | 2019-2025 | Evenity, Enbrel, Krystexxa |
| Ucb, INC. | $1,332.89 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $1,261.31 | 2019-2024 | Tremfya, Simponi Aria, Remicade |
| Pfizer INC. | $1,260.43 | 2019-2024 | |
| Horizon Therapeutics Plc | $719.44 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $575.76 | 2019-2024 | Actemra, Rituxan |
| Lilly USA, LLC | $475.83 | 2019-2024 | Taltz, Olumiant |
| Genzyme Corporation | $473.33 | 2019-2024 | |
| Radius Health, INC. | $389.31 | 2019-2024 | Tymlos |
| Sobi, INC | $382.66 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $372.58 | 2020-2024 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $361.56 | 2019-2022 | |
| Glaxosmithkline, LLC. | $355.27 | 2020-2024 | Benlysta, Nucala |
Show all 40 companies
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sikes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.